| Literature DB >> 27428938 |
Lu Liu1, Zhi-Bin Wang2, Yang Song3, Jing Yang4, Li-Jun Wu5, Bing-You Yang6, Qiu-Hong Wang7, Li-Qian Wang8, Ru-Xuan Wang9, Chun-Juan Yang10.
Abstract
A ultra-high performance liquid chromatography-electrospray ionization tandem mass spectrometry (UHPLC-ESI-MS/MS) method was successfully developed and validated for the identification and determination of eight alkaloids: tetrahydropalmatine (A); palmatine (B); magnoflorine (C); columbamine (D); berberine (E); worenine (F); berberrubine (G) and coptisine (H) in rat plasma, which are the active components in Coptis deltoidea C. Y. cheng et Hsiao (CCY) and Coptis chinensis Franch (CF). The chromatographic separation of analytes was successfully achieved on an Agilent SB-C18 column (1.8 µm, 150 mm × 2.1 mm) using a programme with a mobile phase consisting of acetonitrile and water containing 0.3% acetic acid at a flow rate of 0.25 mL/min. The analytes were detected with a triple quadrupole tandem MS in multiple reaction monitoring (MRM) mode and an electrospray ionization (ESI) source in positive mode. The validated method showed good linearity over a wide concentration range (r² > 0.991), and lower limits of quantification (LLOQ) less than 1.1 ng/mL for all analytes, and matrix effects ranged from 85.2% to 106.8%. The mean extraction recoveries were no less than 86.4%, and the precision and accuracy were within the acceptable limits. All analytes were proven to be stable during sample storage and analysis procedures. The method validation results demonstrated that the proposed method was sensitive, specific, and reliable, which could lay a foundation for the pharmacokinetic study of eight analytes after oral administration of CCY and CF in subsequent studies.Entities:
Keywords: UHPLC-MS/MS; alkaloids; method development; rat plasma
Mesh:
Substances:
Year: 2016 PMID: 27428938 PMCID: PMC6274250 DOI: 10.3390/molecules21070913
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1MS/MS fragmentation patterns of tetrahydropalmatine (A); palmatine (B); magnoflorine (C); columbamine (D); berberine (E); worenine (F); berberrubine (G); coptisine (H); bifendate (I.S.).
Quantitative, Qualifier ions and MS parameters of eight alkaloids and I.S.
| Compounds | Ion Pair ( | Qualifier Ion ( | Fragmentor (V) | Collision Energy (V) | Polarity 1 |
|---|---|---|---|---|---|
| Bifendate (I.S.) | 418.9→342.8 | 284.8 | 78 | 18 | Positive |
| Tetrahydropalmatine | 356.0→192.0 | 165.0 | 159 | 27 | Positive |
| Palmatine | 352.2→336.2 | 308.2 | 158 | 30 | Positive |
| Magnoflorine | 342.2→265.1 | 58.2 | 134 | 22 | Positive |
| Columbamine | 339.2→323.2 | 295.1 | 160 | 29 | Positive |
| Berberine | 336.2→320.1 | 292.2 | 136 | 30 | Positive |
| Worenine | 334.2→261.1 | 233.0 | 181 | 49 | Positive |
| Berberrubine | 322.2→307.2 | 279.2 | 160 | 29 | Positive |
| Coptisine | 320.0→262.0 | 292.2 | 167 | 29 | Positive |
1 The cell accelerator voltage valued of these eight compounds are 5 V.
Gradient elution program of mobile phase.
| Time (min) | A% | B% |
|---|---|---|
| 0 | 65 | 35 |
| 0–2 | 45 | 55 |
| 2–3 | 38 | 62 |
| 3–4.5 | 38 | 62 |
| 4.5–7.0 | 30 | 70 |
| 7.0–7.5 | 65 | 35 |
Figure 2Typical MRM chromatograms of tetrahydropalmatine(A); palmatine (B); magnoflorine (C); columbamine (D); berberine (E); worenine (F); berberrubine (G); coptisine (H); bifendate (I.S.) in rat plasma: (I) Blank rat plasma; (II) Blank plasma spiked with eight alkaloids and I.S.; (III) a plasma sample from a rat 0.25 h after oral administration of Coptis deltoidea C. Y. cheng et Hsiao (CCY) extract; (IV) a plasma sample from a rat 0.75 h after oral administration of Coptis chinensis Franch (CF) extract.
The regression equations, linear ranges and LLOQs for the determination of the analytes in rat plasma.
| Compounds | Regression Equation | Linear Range (ng/mL) | LLOQ (ng/mL) | |
|---|---|---|---|---|
| Tetrahydropalmatine | Y = 15.358X + 1.720 × 10−2 | 0.9964 | 0.5–2028 | 0.5 |
| Palmatine | Y = 112.57X + 5.3976 × 10−2 | 0.9928 | 0.1–428 | 0.1 |
| Magnoflorine | Y = 0.3350X + 3.272 × 10−3 | 0.9906 | 1.1–4320 | 1.1 |
| Columbamine | Y = 2.3498X + 5.334 × 10−2 | 0.9956 | 0.6–2230 | 0.6 |
| Berberine | Y = 18.189X + 0.117 × 10−1 | 0.9985 | 0.1–422 | 0.1 |
| Worenine | Y = 2.4691X + 3.378 × 10−3 | 0.9907 | 0.6–2220 | 0.6 |
| Berberrubine | Y = 12.738X + 1.730 × 10−3 | 0.9945 | 1.1–4420 | 1.1 |
| Coptisine | Y = 2.5543X + 3.665 × 10−2 | 0.9905 | 0.2–800 | 0.2 |
Precision and accuracy of the determination of eight alkaloids in rat plasma (n = 18, 6 replicates per day for 3 days).
| Compounds | Spiked Concentration (ng/mL) | Measured CONC (ng/mL) | Accuracy (%) | Intra-Day Precision (%) | Inter-Day Precision (%) |
|---|---|---|---|---|---|
| Tetrahydropalmatine | 0.5 | 0.5 ± 0.1 | −1.0 | 17.6 | 18.8 |
| 2.0 | 2.1 ± 0.3 | −3.4 | 13.6 | 3.7 | |
| 50.7 | 53.1 ± 6.9 | −3.0 | 12.9 | 12.9 | |
| 1622 | 1759 ± 172 | 8.4 | 9.1 | 13.8 | |
| Palmatine | 0.1 | 0.1 ± 0.02 | 8.5 | 18.5 | 15.6 |
| 0.4 | 0.5 ± 0.07 | 11.2 | 13.4 | 11.9 | |
| 10.7 | 11.1 ± 1.5 | 3.4 | 14.2 | 10.3 | |
| 342 | 368 ± 41.8 | 7.5 | 11.8 | 6.7 | |
| Magnoflorine | 1.1 | 1.3 ± 0.1 | 14.1 | 11.7 | 6.6 |
| 4.3 | 4.3 ± 1.1 | 7.1 | 14.3 | 4.7 | |
| 108 | 116 ± 13.8 | 7.5 | 12.0 | 10.3 | |
| 3456 | 3817 ± 485 | 10.4 | 12.5 | 14.4 | |
| Columbamine | 0.6 | 0.6 ± 0.04 | −14.4 | 14.9 | 14.2 |
| 2.2 | 2.5 ± 0.3 | 9.8 | 14.3 | 3.5 | |
| 55.8 | 53.9 ± 6.7 | −3.4 | 12.3 | 13.5 | |
| 1784 | 1713 ± 193 | −4.0 | 11.0 | 13.4 | |
| Berberine | 0.1 | 0.1 ± 0.01 | −2.9 | 10.0 | 17.8 |
| 0.4 | 0.5 ± 0.1 | 5.5 | 14.3 | 6.3 | |
| 11.1 | 10.7 ± 1.0 | −7.3 | 8.7 | 12.4 | |
| 354 | 317 ± 30.7 | −10.4 | 10.0 | 6.8 | |
| Worenine | 0.6 | 0.6 ± 0.1 | −0.1 | 16.8 | 13.9 |
| 2.2 | 2.2 ± 0.3 | −4.3 | 14.0 | 10.3 | |
| 55.5 | 51.3 ± 6.1 | −7.4 | 12.0 | 12.0 | |
| 1776 | 1715 ± 90.6 | −3.4 | 4.9 | 7.6 | |
| Berberrubine | 1.1 | 1.1 ± 1.1 | 0.8 | 14.3 | 9.2 |
| 4.4 | 5.3 ± 0.6 | 14.1 | 11.6 | 8.4 | |
| 111 | 112 ± 14.0 | 1.5 | 13.1 | 6.2 | |
| 3536 | 3949 ± 437 | 11.7 | 11.3 | 9.4 | |
| Coptisine | 0.2 | 0.2 ± 0.03 | 13.4 | 13.8 | 1.8 |
| 0.8 | 0.8 ± 0.1 | 2.1 | 12.7 | 9.9 | |
| 20.0 | 22.4 ± 2.6 | 11.8 | 11.9 | 9.0 | |
| 640 | 555 ± 70.3 | −13.3 | 13.1 | 8.4 |
Matrix effects and extraction recovery for the analytes in rat plasma (n = 6).
| Compounds | Spiked Concentration (ng/mL) | Matrix Effect | Extraction Recovery | ||
|---|---|---|---|---|---|
| Mean (%) | RSD (%) | Mean (%) | RSD (%) | ||
| Tetrahydropalmatine | 2.0 | 105.1 | 8.4 | 94.8 | 14.2 |
| 50.7 | 100.5 | 8.2 | 95.9 | 7.8 | |
| 1622 | 104.4 | 7.2 | 94.7 | 4.2 | |
| Palmatine | 0.4 | 101.7 | 6.2 | 93.1 | 13.6 |
| 10.7 | 93.7 | 11.2 | 86.4 | 5.1 | |
| 342 | 101.8 | 12.5 | 95.6 | 3.0 | |
| Magnoflorine | 4.3 | 99.1 | 11.4 | 93.4 | 5.5 |
| 108 | 85.2 | 13.1 | 90.0 | 4.1 | |
| 3456 | 98.5 | 13.4 | 86.4 | 14.3 | |
| Columbamine | 2.2 | 100.0 | 13.5 | 100.0 | 6.2 |
| 55.8 | 98.8 | 5.9 | 90.8 | 8.9 | |
| 1784 | 101.2 | 9.6 | 98.4 | 12.0 | |
| Berberine | 0.4 | 101.8 | 12.3 | 92.3 | 8.2 |
| 11.1 | 100.5 | 9.3 | 93.2 | 4.0 | |
| 354 | 102.3 | 5.0 | 97.6 | 11.1 | |
| Worenine | 2.2 | 92.5 | 7.8 | 98.9 | 12.1 |
| 55.5 | 87.7 | 10.0 | 88.0 | 9.8 | |
| 1776 | 105.6 | 5.1 | 93.4 | 1.8 | |
| Berberrubine | 4.4 | 94.7 | 2.4 | 90.6 | 10.2 |
| 111 | 98.0 | 11.3 | 91.2 | 2.6 | |
| 3536 | 100.8 | 4.3 | 93.4 | 11.5 | |
| Coptisine | 0.8 | 106.8 | 3.9 | 92.3 | 7.4 |
| 20.0 | 99.5 | 5.7 | 92.2 | 4.2 | |
| 640 | 89.1 | 5.1 | 89.0 | 8.4 | |
| I.S. | 2000 | 98.2 | 11.1 | 88.7 | 13.7 |
Stabilities of the analytes in rat plasma (n = 6).
| Compounds | Spiked Concentration (ng/mL) | Stability (% RE) | |||
|---|---|---|---|---|---|
| Freeze-Thaw | Short Term | Long Term | Post Preparative | ||
| Tetrahydropalmatine | 2.0 | −10.9 | 13.3 | 13.6 | 2.8 |
| 50.7 | −13.8 | 12.5 | 13.5 | −0.8 | |
| 1622 | 6.2 | 8.0 | 14.5 | −5.5 | |
| Palmatine | 0.4 | −0.2 | 14.9 | 5.9 | 8.5 |
| 10.7 | −2.3 | −9.6 | −11.2 | −12.4 | |
| 342 | −2.8 | −1.7 | 12.9 | −3.0 | |
| Magnoflorine | 4.3 | 12.2 | 10.6 | 9.4 | 10.7 |
| 108 | −3.4 | 14.1 | 13.6 | −1.0 | |
| 3456 | 13.3 | 7.4 | 13.2 | 6.7 | |
| Columbamine | 2.2 | 12.3 | 11.9 | 11.7 | 6.9 |
| 55.8 | −10.2 | −0.3 | −2.5 | −11.2 | |
| 1784 | 1.9 | −4.2 | −5.9 | −1.8 | |
| Berberine | 0.4 | 9.4 | 1.2 | 2.4 | 2.9 |
| 11.1 | −12.5 | −1.0 | −14.6 | 2.6 | |
| 354 | −12.5 | −4.1 | −11.0 | −4.2 | |
| Worenine | 2.2 | 5.6 | −12.9 | −7.8 | 12.3 |
| 55.5 | 4.7 | 8.9 | 9.9 | 5.6 | |
| 1776 | −5.4 | −9.8 | −4.3 | −6.6 | |
| Berberrubine | 4.4 | 8.1 | 8.2 | 8.0 | 13.9 |
| 111 | 11.3 | 0.01 | −2.5 | 4.4 | |
| 3536 | 6.9 | 8.6 | −0.6 | 11.2 | |
| Coptisine | 0.8 | 13.1 | −14.4 | 8.7 | 5.1 |
| 20.0 | 2.1 | −6.1 | −5.6 | 1.8 | |
| 640 | 8.4 | −4.8 | 0.6 | 12.2 | |
Figure 3Mean concentration-time profiles of tetrahydropalmatine (A); palmatine (B); magnoflorine (C); columbamine (D); berberine (E); worenine (F); berberrubine (G); coptisine (H) in rat plasma after oral administration of CCY and cf. Each point represents the mean ± SD (n = 14).